Literature DB >> 25622978

Current management of lesions associated with an increased risk of breast cancer.

Monica Morrow1, Stuart J Schnitt2, Larry Norton3.   

Abstract

High-risk breast lesions, which comprise benign lesions and in situ carcinomas (lobular carcinoma in situ and ductal carcinoma in situ), are clinically, morphologically, and biologically heterogeneous and are associated with an increased risk of invasive breast cancer development, albeit to varying degrees. Recognition and proactive management of such lesions can help to prevent progression to invasive disease, and might, therefore, reduce breast cancer incidence, morbidity, and mortality. However, this opportunity comes with the possibility of overdiagnosis and overtreatment, necessitating risk-based intervention. Notably, despite the progress in defining the molecular changes associated with carcinogenesis, alterations identifying the individuals with high-risk lesions that will progress to invasive carcinoma remain to be identified. Thus, until reproducible clinicopathological or molecular features predicting an individual's risk of breast cancer are found, management strategies must be defined by population-level risks as determined by models such as the Gail or IBIS models, as well as patient attitudes toward the risks and benefits of interventions. Herein, we review the contemporary approaches to diagnosis and management of high-risk breast lesions. Progress in this area will ultimately be dependent on the ability to individualize risk prediction through better definition of the key drivers in the carcinogenic process.

Entities:  

Mesh:

Year:  2015        PMID: 25622978     DOI: 10.1038/nrclinonc.2015.8

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  93 in total

1.  Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer?

Authors:  Daniel X Choi; Anne A Eaton; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2012-11-19       Impact factor: 5.344

Review 2.  Recommendations for women with lobular carcinoma in situ (LCIS).

Authors:  Bridget A Oppong; Tari A King
Journal:  Oncology (Williston Park)       Date:  2011-10       Impact factor: 2.990

3.  Long-term follow-up of in situ carcinoma of the breast.

Authors:  V Eusebi; E Feudale; M P Foschini; A Micheli; A Conti; C Riva; S Di Palma; F Rilke
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

4.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

Review 5.  Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast--a review.

Authors:  M Hussain; G H Cunnick
Journal:  Eur J Surg Oncol       Date:  2011-04       Impact factor: 4.424

6.  Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study.

Authors:  David L Page; Peggy A Schuyler; William D Dupont; Roy A Jensen; W Dale Plummer; Jean F Simpson
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

7.  Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy.

Authors:  Miraj G Shah-Khan; Xochiquetzal J Geiger; Carol Reynolds; James W Jakub; Elizabeth R Deperi; Katrina N Glazebrook
Journal:  Ann Surg Oncol       Date:  2012-07-31       Impact factor: 5.344

8.  Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group.

Authors:  G L Ottesen; H P Graversen; M Blichert-Toft; K Zedeler; J A Andersen
Journal:  Am J Surg Pathol       Date:  1993-01       Impact factor: 6.394

Review 9.  Progression from ductal carcinoma in situ to invasive breast cancer: revisited.

Authors:  Catherine F Cowell; Britta Weigelt; Rita A Sakr; Charlotte K Y Ng; James Hicks; Tari A King; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2013-07-12       Impact factor: 6.603

10.  Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.

Authors:  Robin M Ciocca; Tianyu Li; Gary M Freedman; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2008-05-28       Impact factor: 5.344

View more
  24 in total

1.  Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.

Authors:  Maeve Mullooly; Zeina G Khodr; Cher M Dallal; Sarah J Nyante; Mark E Sherman; Roni Falk; Linda M Liao; Jeffrey Love; Louise A Brinton; Gretchen L Gierach
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

2.  Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.

Authors:  Wen Bu; Zhenyu Liu; Weiyu Jiang; Chandandeep Nagi; Shixia Huang; Dean P Edwards; Eunji Jo; Qianxing Mo; Chad J Creighton; Susan G Hilsenbeck; Andrew D Leavitt; Michael T Lewis; Stephen T C Wong; Yi Li
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

3.  Apparent diffusion coefficient values may help predict which MRI-detected high-risk breast lesions will upgrade at surgical excision.

Authors:  Safia Cheeney; Habib Rahbar; Brian N Dontchos; Sara H Javid; Mara H Rendi; Savannah C Partridge
Journal:  J Magn Reson Imaging       Date:  2017-02-09       Impact factor: 4.813

Review 4.  Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment.

Authors:  Savitri Krishnamurthy; Therese Bevers; Henry M Kuerer; Benjamin Smith; Wei Tse Yang
Journal:  AJR Am J Roentgenol       Date:  2016-12-08       Impact factor: 3.959

5.  A Multistage Murine Breast Cancer Model Reveals Long-Lived Premalignant Clones Refractory to Parity-Induced Protection.

Authors:  Shuo Li; Shelley A Gestl; Edward J Gunther
Journal:  Cancer Prev Res (Phila)       Date:  2019-11-07

6.  Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.

Authors:  Xiaoxian Li; Zhongliang Ma; Toncred M Styblo; Cletus A Arciero; Haibo Wang; Michael A Cohen
Journal:  Breast Cancer Res Treat       Date:  2020-10-17       Impact factor: 4.872

Review 7.  Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review.

Authors:  Kelly L Mooney; Lawrence W Bassett; Sophia K Apple
Journal:  Mod Pathol       Date:  2016-08-19       Impact factor: 7.842

Review 8.  American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications.

Authors:  Stuart J Schnitt; Edi Brogi; Yunn-Yi Chen; Tari A King; Sunil R Lakhani
Journal:  Ann Diagn Pathol       Date:  2020-02-15       Impact factor: 2.090

9.  Breast Cancer Detection by Preoperative Imaging in Reduction Mammaplasty Patients: A Single Center Study of 918 Patients.

Authors:  Päivi A Merkkola-von Schantz; Susanna M C Kauhanen; Tiina A Jahkola; Leena A Krogerus; Katja S Hukkinen
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

10.  Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression.

Authors:  Peng-Bo Yang; Pei-Pei Hou; Fu-Yuan Liu; Wen-Bin Hong; Hang-Zi Chen; Xiao-Yu Sun; Peng Li; Yi Zhang; Cui-Yu Ju; Li-Juan Luo; Sheng-Fu Wu; Jia-Xin Zhou; Zhi-Jing Wang; Jian-Ping He; Li Li; Tong-Jin Zhao; Xianming Deng; Tianwei Lin; Qiao Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.